Lasa Supergenerics Limited (LASA) - Net Assets
Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has net assets worth Rs563.42 Million INR (≈ $6.09 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs716.03 Million ≈ $7.74 Million USD) and total liabilities (Rs152.61 Million ≈ $1.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Lasa Supergenerics Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs563.42 Million |
| % of Total Assets | 78.69% |
| Annual Growth Rate | 1.3% |
| 5-Year Change | -47.32% |
| 10-Year Change | N/A |
| Growth Volatility | 26.23 |
Lasa Supergenerics Limited - Net Assets Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's net assets have evolved over time, based on quarterly financial data. Also explore Lasa Supergenerics Limited balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual net assets of Lasa Supergenerics Limited from 2017 to 2025. For live valuation and market cap data, see market cap of Lasa Supergenerics Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs837.13 Million ≈ $9.05 Million |
-13.41% |
| 2024-03-31 | Rs966.76 Million ≈ $10.46 Million |
-18.27% |
| 2023-03-31 | Rs1.18 Billion ≈ $12.79 Million |
-25.08% |
| 2022-03-31 | Rs1.58 Billion ≈ $17.07 Million |
-0.65% |
| 2021-03-31 | Rs1.59 Billion ≈ $17.19 Million |
+12.34% |
| 2020-03-31 | Rs1.41 Billion ≈ $15.30 Million |
+34.35% |
| 2019-03-31 | Rs1.05 Billion ≈ $11.39 Million |
-10.26% |
| 2018-03-31 | Rs1.17 Billion ≈ $12.69 Million |
+55.43% |
| 2017-03-31 | Rs754.94 Million ≈ $8.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Lasa Supergenerics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61020500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs501.01 Million | 59.85% |
| Other Comprehensive Income | Rs515.77 Million | 61.61% |
| Other Components | Rs437.26 Million | 52.23% |
| Total Equity | Rs837.13 Million | 100.00% |
Lasa Supergenerics Limited Competitors by Market Cap
The table below lists competitors of Lasa Supergenerics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Celtic plc
LSE:CCPC
|
$4.33 Million |
|
Binani Industries Limited
NSE:BINANIIND
|
$4.34 Million |
|
Zenvia Inc
NASDAQ:ZENV
|
$4.34 Million |
|
Groupe JAJ
PA:GJAJ
|
$4.34 Million |
|
The Dixie Group Inc
NASDAQ:DXYN
|
$4.33 Million |
|
MOVIE GAMES S.A. ZY1
F:2LH
|
$4.33 Million |
|
NCL International Logistics Public Company Limited
BK:NCL
|
$4.33 Million |
|
Gungnir Resources Inc
V:GUG
|
$4.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lasa Supergenerics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 966,762,000 to 837,133,000, a change of -129,629,000 (-13.4%).
- Net loss of 147,575,000 reduced equity.
- Share repurchases of 17,500,000 reduced equity.
- New share issuances of 17,500,000 increased equity.
- Other factors increased equity by 17,946,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs-147.57 Million | -17.63% |
| Share Repurchases | Rs17.50 Million | -2.09% |
| Share Issuances | Rs17.50 Million | +2.09% |
| Other Changes | Rs17.95 Million | +2.14% |
| Total Change | Rs- | -13.41% |
Book Value vs Market Value Analysis
This analysis compares Lasa Supergenerics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.22x to 0.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | Rs36.62 | Rs8.00 | x |
| 2018-03-31 | Rs51.62 | Rs8.00 | x |
| 2019-03-31 | Rs46.05 | Rs8.00 | x |
| 2020-03-31 | Rs34.78 | Rs8.00 | x |
| 2021-03-31 | Rs39.07 | Rs8.00 | x |
| 2022-03-31 | Rs31.39 | Rs8.00 | x |
| 2023-03-31 | Rs23.61 | Rs8.00 | x |
| 2024-03-31 | Rs19.30 | Rs8.00 | x |
| 2025-03-31 | Rs16.73 | Rs8.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lasa Supergenerics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.36%
- • Asset Turnover: 1.40x
- • Equity Multiplier: 1.21x
- Recent ROE (-17.63%) is below the historical average (-6.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 3.13% | 1.19% | 0.87x | 3.02x | Rs-51.92 Million |
| 2018 | 10.52% | 5.07% | 0.85x | 2.44x | Rs6.06 Million |
| 2019 | -11.43% | -7.09% | 0.66x | 2.45x | Rs-225.60 Million |
| 2020 | 2.56% | 2.17% | 0.72x | 1.64x | Rs-105.18 Million |
| 2021 | 14.33% | 11.25% | 0.97x | 1.31x | Rs68.86 Million |
| 2022 | -3.38% | -3.89% | 0.66x | 1.32x | Rs-211.20 Million |
| 2023 | -32.65% | -29.81% | 0.79x | 1.39x | Rs-504.49 Million |
| 2024 | -22.48% | -20.83% | 0.69x | 1.56x | Rs-313.98 Million |
| 2025 | -17.63% | -10.36% | 1.40x | 1.21x | Rs-231.29 Million |
Industry Comparison
This section compares Lasa Supergenerics Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lasa Supergenerics Limited (LASA) | Rs563.42 Million | 3.13% | 0.27x | $4.33 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more